Treatment of lung cancer using hedgehog pathway inhibitors

• US 10,328,072 B2
• Filed: 04/30/2018
• Issued: 06/25/2019
• Est. Priority Date: 04/17/2013
• Status: Active Grant

• Current Assignee: Inhibitor Therapeutics, Inc. (Mayne Pharma)
• Original Assignee: Inhibitor Therapeutics, Inc. (Mayne Pharma)
• Inventors: Virca, Nicholas J., O'Donnell, Jr., Francis E.
• Primary Examiner(s): Rao, Savitha M
• Application Number:
  US15/966,613
• Publication Number:
  US 20180243295A1
• Time in Patent Office: 421 Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/519 ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61P 13/08 of the prostate
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 2333/96455 Kallikrein (3.4.21.34; 3.4.21.35)
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Abstract

The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.

Claims

1. A method for treating lung cancer in a subject, comprising orally administering a composition comprising a solid dispersion of a Hedgehog pathway (HhP) inhibitor and a polycarboxylic acid polymer, to the subject, wherein the HhP inhibitor comprises itraconazole, or a pharmaceutically acceptable salt, prodrug, stereoisomer, or active metabolite thereof;

and administering an antifolate to the subject, and wherein;

(a) the composition is orally administered in an effective amount to achieve a plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor, or (b) the composition is orally administered at a dose in the range of 100 mg to 600 mg HhP inhibitor per day.

2. The method of claim 1, wherein the HhP inhibitor comprises itraconazole, or a pharmaceutically acceptable salt or stereoisomer thereof.

3. The method of claim 1, wherein the composition is orally administered at a dose in the range of 100 mg to 600 mg of HhP inhibitor per day.

4. The method of claim 2, wherein the HhP inhibitor therapy comprises administration of a capsule or powder of 50 mg of the itraconazole, or a pharmaceutically acceptable salt, or stereoisomer thereof, twice per day.

5. The method of claim 3, wherein the composition is in the form of a capsule.

6. The method of claim 1, wherein the composition is orally administered in an effective amount to achieve a plasma trough level of at least 1,000 ng/mL of the HhP inhibitor.

7. The method of claim 1, wherein the composition is administered in an effective amount to achieve a plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor after about 4 weeks of initiation of treatment with the HhP inhibitor.

8. The method of claim 1, wherein the composition is administered in an effective amount to achieve a plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor within about 2 weeks after initiation of treatment, and to maintain the plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor for the duration of the treatment.

9. The method of claim 1, further comprising measuring the plasma level of the HhP inhibitor, or a metabolite thereof, in the subject one or more times.

10. The method of claim 9, wherein said measuring is carried out one or more times about 4 weeks after initiation of treatment with the HhP inhibitor.

11. The method of claim 1, further comprising measuring the plasma level of the HhP inhibitor, or a metabolite thereof, one or more times in a period of time from about 4 weeks to about 12 weeks.

12. The method of claim 11, further comprising increasing a subsequent dose of the HhP inhibitor if the plasma trough level of at least about 1,000 ng/mL of the HhP inhibitor is not maintained.

13. The method of claim 11, further comprising reducing a subsequent dose of an HhP inhibitor if the plasma trough level at about 4 weeks is at least 1000 ng/mL and the patient is experiencing one or more side effects.

14. The method of claim 1, wherein the lung cancer is non-small-cell lung cancer.

15. The method of claim 1, further comprising monitoring the proliferation disorder in the subject, wherein a lack of clinical response in the proliferation disorder to the treatment is indicative that the plasma trough level of the HhP inhibitor should be increased further above about 1000 ng/mL, and wherein the occurrence of a clinical response and a plasma trough level of the HhP inhibitor substantially higher than about 1000 ng/mL indicates that one or more subsequent doses of the HhP inhibitor can be reduced.

16. The method of claim 1, further comprising monitoring the proliferation disorder in the subject, wherein a lack of clinical response in the proliferation disorder to the treatment, after about four weeks of said administering, is indicative of a need to increase the dose of the HhP inhibitor, or increase the frequency of the dose of the HhP inhibitor, or administer an additional HhP inhibitor that inhibits the HhP by a different mechanism than the previously administered HhP inhibitor, or a combination of two or more of the foregoing.

17. The method of claim 1, wherein the composition is orally administered at a dose in the range of 100 mg to 600 mg of HhP inhibitor per day, and wherein the method further comprises administering a platinum-based chemotherapeutic agent to the subject.

18. The method of claim 17, wherein the platinum-based chemotherapeutic agent is selected from the group consisting of carboplatin, cisplatin, or oxaliplatin, satraplatin, picoplatin, nedaplatin, and triplatin.

19. The method of claim 1, wherein the antifolate is pemetrexid.

20. The method of claim 1, wherein the lung cancer is non-squamous non-small-cell lung cancer.

21. The method of claim 14, wherein the method further comprises administering a chemotherapeutic agent to the subject.

22. The method of claim 21, wherein the chemotherapeutic agent is gemcitabine.

23. The method of claim 21, wherein the chemotherapeutic agent is a taxane.

24. The method of claim 23, wherein the taxane is docetaxel.